公开(公告)号：EP2023937A2

公开(公告)日：2009-02-18

申请号：EP07797577.9

申请日：2007-05-18

申请人： Alnylam Pharmaceuticals Inc. ,  The Scripps Research Institute

发明人： CONSTIEN, Rainer ,  BRAMLAGE, Birgit ,  TAN, Pamela ,  VORNLOCHER, Hans-Peter ,  BALCH, William

IPC分类号： A61K31/70

CPC分类号： C12N15/113 ,  C12N2310/14 ,  C12N2310/3515

摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.

公开(公告)号：EP1896084A2

公开(公告)日：2008-03-12

申请号：EP06785707.8

申请日：2006-06-27

申请人： Alnylam Pharmaceuticals Inc.

发明人： AKINC, Akin ,  DE FOUGEROLLES, Antonin ,  VORNLOCHER, Hans-Peter ,  HADWIGER, Philipp ,  BRAMLAGE, Birgit

IPC分类号： A61K48/00

CPC分类号： C12N15/113 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3521

摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1α, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.

公开(公告)号：EP1999260A2

公开(公告)日：2008-12-10

申请号：EP07753837.9

申请日：2007-03-23

申请人： NOVARTIS AG ,  NOVARTIS-PHARMA GMBH

发明人： BENSON, John ,  BRAMLAGE, Birgit ,  FITZGERALD, Kevin ,  TAN, Pamela ,  VORNLOCHER, Hans-Peter

IPC分类号： C12N15/11 ,  A61K31/713 ,  C07H21/00 ,  A61P31/20

CPC分类号： C12N15/1137 ,  C12N15/111 ,  C12N15/1131 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3515 ,  C12N2320/31 ,  C12N2310/3521

摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.